SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 262.98 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 121.22 |
| Book Value / Share | 0.16 |
| Price / Book | n/a |
| NCAV ($M) | 40.22 |
| NCAV / Share | 0.05 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.58 |
| Return on Assets (ROA) | -1.31 |
| Return on Equity (ROE) | -1.46 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.76 |
| Current Ratio | 5.76 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 48.72 |
| Assets | 129.72 |
| Liabilities | 8.50 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ra Capital Management, L.p. | 7.70 | ||
| 13G | Deep Track Capital, LP | 7.65 | ||
| 13G/A | Point72 Asset Management, L.P. | 7.40 | 58.63 | |
| 13G/A | Rands Peter David | 4.34 | -15.34 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 495,637 | 375,517 | 131.99 | |
| 778,397 | 255,135 | 305.09 | |
| 880,713 | 250,102 | 352.14 | |
| 744,069 | 213,230 | 348.95 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CLDI – Calidi Biotherapeutics, Inc. | CPHI – China Pharma Holdings, Inc. |
| CVM – CEL-SCI Corporation | IBIO – iBio, Inc. |
| IGC – IGC Pharma, Inc. |
Financial data and stock pages provided by
Fintel.io